02561 Overview

Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.

Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.

Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.

Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.

Stock Performance Overview: Various stocks such as VISEN PHARMA-B and AKESO show mixed performance, with VISEN PHARMA-B down by 1.138% and AKESO up by 1.002%.

Short Selling Activity: Significant short selling activity is noted across several stocks, including Zai Lab and INNOVENT BIO, with short selling ratios reaching as high as 30.955% for Zai Lab.

Analyst Ratings: Most stocks listed, including INNOVENT BIO and KEYMED BIO-B, are rated as "Outperform," indicating positive expectations from analysts.

Market Trends: The report highlights the top 10 HK stocks with the highest net buys and sells by Southbound funds, reflecting current market trends and investor interests.

Market Growth: Chinese biotech stocks in Hong Kong have surged by 154% year-to-date, significantly outperforming the Hang Seng Index's 34% growth, indicating a shift in market perception of domestic pharmaceutical innovation.

Investment Outlook: Morgan Stanley predicts that the US Federal Reserve's rate cuts will boost risk appetite, directing funds towards growth sectors like Chinese biotech, while emphasizing that stock performance will still depend on fundamentals such as commercialization and R&D progress.